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interviews with relevant stakeholders, questions about the target patient popula-
tion, the intervention and standard care could be answered. Some issues arose
such as variation in standard care and the definition of risk categories. Evidence on
the prognostic value of some biomarkers was also found to be inconsistent. Deci-
sion-analytic modelling could be applied to synthesize all available evidence and
estimate the health benefits and costs of the intervention and standard care op-
tions. The influence of the diagnostic accuracy of the test and assumptions about
the patient population and treatment outcomes could be evaluated. Not all ques-
tions regarding the generalizability of the results to other settings could be an-
swered by these techniques. CONCLUSIONS: The role of early HTA for companion
diagnostics is to identify the gaps in evidence on the clinical and economic value of
biomarkers, variation in standard care, and key stakeholders and their preferences.
This information is necessary for forecasting the issues that will be encountered
when positioning a pharmacogenomic test in the market.
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The objective is to automate the migration of complex health economics Excel
models based on Markov chains to modern software platforms, such as Mobile or
Web. In this research project, we have developed a software solution that is capable
of transforming a Microsoft Excel model into a self-contained platform-indepen-
dent programming module. This module fully preserves the original model along
with cell values, formulas and dependencies, and is capable of running the model
independently from the Microsoft Excel environment. The module is used as a
basis for creating web and mobile applications supporting calculations identical to
that in Excel model. These applications will give the user means to manipulate
model inputs and see the results of his actions immediately without having the full
model delivered, thus preserving the confidentiality of proprietary data and algo-
rithms. By using our method, several Excel based Markov cohort models with more
than 1000 cycles were transformed and used as a basis for development of web-
based and iPad applications for health care decision making. These applications
showed performance comparable to Microsoft Excel and complete outcomes cor-
relation with the original model. With the proposed solution, mature Excel models
developed over the years in various institutions can be connected with modern
information technologies in a fast and reliable way. Our method makes automated
model transformation possible without human intrusion into a stable model core.
By eliminating the dependency on Microsoft Excel, we open new ways for integra-
tion of time-proven Excel models with modern software platforms, such as the
Web or Mobile.
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OBJECTIVES: To identify real-world incidence and related costs of hypoglycemia
among T2DM patients initiating insulin glargine (GLA). METHODS: Patient-level
data from 6 published observational retrospective studies using health plan claim
databases were pooled. Included were T2DM patients with continuous health plan
coverage for 6 months before and 1 year after initiation, who were previously on
oral antidiabetic drugs (OADs) or glucagon-like peptide-1 (GLP-1) analogs and ini-
tiated GLA (2007-2009) via disposable pen (GLA-P) or vial/syringe (GLA-V). In each
study, observed differences between the two cohorts were removed by propensity
score matching. Hypoglycemia and associated health care costs were measured
over a 1-year follow-up period. RESULTS: Included were 14,911 GLA-P patients and
8,187 GLA-V patients (age 54.1 years, 53.5% men, mean Charlson Comorbidity Index
0.55, # of OADs 2.45, A1C 9.34% where available). During follow-up, prevalence rates
of any hypoglycemia and inpatient/emergency room (ER)-related hypoglycemia
were low overall, particularly for GLA-P (5.49% vs 7.70% and 1.60% vs 3.26%; both
P0.0001). Incidence rates of any hypoglycemia and inpatient/ER-related hypogly-
cemia were 25.7 and 3.8 events/100 patient years, and lower for GLA-P (any: 20.4 vs
35.5 events/100 patient years; ER-related: 2.6 vs 6.1 events/100 patient years; both
P0.0001). Hypoglycemia-related costs were lower for GLA-P ($225 vs $417;
P0.001). Hypoglycemia-related costs contributed 0.75% of overall health care
costs and 1.5% of diabetes-related health care costs across both cohorts; in the
GLA-P cohort the contribution was 0.55% and 1.07% (both P0.001) of overall and
diabetes-related costs, respectively. A1C reduction from baseline (N1,896) was
larger for GLA-P (1.22% vs 0.86%, P0.0012), and correlated with higher inci-
dence of hypoglycemia (r0.151; P0.0001). CONCLUSIONS: Patients initiating
insulin glargine treatment showed low rates of hypoglycemia, especially when
using a disposable pen device. Hypoglycemia-related costs were low, contributing
a very small proportion to overall and diabetes-related health care costs.
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OBJECTIVES: The use of standard immediate release metformin (MIR) two or three
times daily has been associated with gastrointestinal adverse events (GIAE). Met-
formin XR (MXR) is a once a day extended release formulation that offers a poten-
tial benefit of a decrease in the frequency of GIAE and increased adherence rates in
patients diagnosed with Type 2 Diabetes Mellitus (T2DM). This systematic review
identifies published evidence regarding the efficacy, safety, and adherence of MXR
relative to MIR in the treatment of T2DM. METHODS: We searched relevant bibli-
ographic databases, internet and grey literature, and included all studies with an
analytical or observational design. We assessed the quality of all selected studies
following the Cochrane Collaboration recommendations. When possible, we cal-
culated the mean global effect of MXR vs. MIR for clinical outcomes. RESULTS: The
search identified 81 studies of which 10 met inclusion/exclusion criteria for anal-
ysis. The quality of these 10 studies was generally poor. Efficacy results of 187
patients were included in a meta-analysis that estimated the mean difference with
respect to baseline measurements. Glycosylated hemoglobin (HbA1c) control, fast-
ing plasma glucose and lipid control was similar in both treatments (MD0.01
CI95%-0.38-0.41; MD0.32 CI95%-0.25-0.89; MD0.16 CI95%-0.23-0.54, respec-
tively). The frequency of GIAE was meta-analyzed using data from 1,045 patients,
and the global Relative Risk was estimated (RR 0.97; CI95%0.80-1.19). Patients
treated with MXR experienced a significantly lower incidence of nausea (RR0.82;
CI95%0.46-1.95) and dyspepsia (RR0.64; CI95%0.29-1.43) than patients on MIR.
Adherence was reported in two studies, showing that patients treated with MXR
have a significantly higher adherence to treatment than MIR cohorts.
CONCLUSIONS: Treatment once a day with MXR tablets has comparable efficacy to
a two or three times daily dosage with MIR. MXR offers the benefit of increased
adherence to treatment, and a lower frequency of nausea and dyspepsia compared
to MIR.
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OBJECTIVES: The Initiation of New Injectable Treatment Introduced after Anti-
diabetic Therapy with Oral-only Regimens (INITIATOR) study aims to investigate
real-world outcomes among T2DM patients failing oral antidiabetic drugs (OADs)
and initiating injectable therapy with insulin glargine (GLA-P) or the glucagon-like
peptide 1 analog liraglutide (LIRA). This analysis reports treatment pattern data
from the pilot retrospective study phase of INITIATOR. METHODS: Two indepen-
dent administrative claims databases from OptumInsight™ (OI) and HealthCore®
(HC) were assessed retrospectively. Data were included from adult T2DM patients
previously on OADs only, initiating GLA-P or LIRA injectable therapy (January–July
2010) with continuous health care coverage during the 6 months before (baseline),
and 9 (OI) or 12 months (HC) after initiation (follow-up). Baseline characteristics,
treatment patterns, and outcomes among GLA-P and LIRA cohorts were assessed
descriptively. RESULTS: 2,684 patients were included (OI: GLA-P n610, LIRA
n365; HC: GLA-P n1,188, LIRA n521). Compared to LIRA patients, GLA-P initia-
tors were older (56 years vs 53 years; P0.001), less obese (9.2%-12% vs 18%-19%; OI:
P0.01, HC: P0.001), had higher comorbidity (CCI 1.1-1.2 vs 0.6-0.7; P0.001) and
higher A1C (9.1%-9.7% vs 7.7%-7.9%; P0.001), and were much less likely to have
baseline A1C 7.0% (9%-11% vs 30%-34%; P0.001).During follow-up, the 9-month
(OI) treatment persistence rate was 63.1% for GLA-P and 52.1% for LIRA; the 12-
month (HC) rate was 60.2% for GLA-P and 50.9% for LIRA. Total annualized all-cause
health care costs for GLA-P vs LIRA, respectively, were $16,560 vs $14,984 (OI), and
$16,466 vs $14,579 (HC). Study drugs contributed 7% (GLA-P) and 17%-19% (LIRA) to
the total costs. CONCLUSIONS: GLA-P and LIRA are prescribed to very different
T2DM patients in a real-world setting, with about 1/3 of LIRA initiators character-
ized by baseline A1C 7.0%. These differences in patient characteristics need to be
taken into account when conducting related comparative effectiveness research.
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OBJECTIVES: For the management of T2DM using combination therapy with PIO
and DPP4i, there is no consensus on whether to initiate both drugs simultaneously
or start with PIO followed by sequential addition of DPP4i. We aimed to assess
impact of initial vs. sequential combination therapy with PIO and DPP4i on HbA1C
reduction. METHODS: A chart review was conducted among people with T2DM to
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